(177)Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians

PURPOSE: There is increasing evidence for convincing efficacy and safety of (177)Lu-labled prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for metastatic castration-resistant prostate cancer (mCRPC). However, data are not available regarding the feasibility of (177)Lu-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Ting, Zhang, Lulu, Yu, Fei, Yao, Xiaochen, Wu, Wenyu, Zhang, Pengjun, Shi, Liang, Zang, Shiming, Meng, Qingle, Ni, Yudan, Shao, Guoqiang, Qiu, Xuefeng, Ai, Shuyue, Jia, Ruipeng, Guo, Hongqian, Wang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988071/
https://www.ncbi.nlm.nih.gov/pubmed/35402274
http://dx.doi.org/10.3389/fonc.2022.835956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988071/
https://www.ncbi.nlm.nih.gov/pubmed/35402274
http://dx.doi.org/10.3389/fonc.2022.835956

Ejemplares similares